Loading...
XNASKMDA
Market cap349mUSD
Dec 24, Last price  
6.05USD
1D
0.00%
1Q
14.15%
Jan 2017
11.01%
IPO
-42.60%
Name

Kamada Ltd

Chart & Performance

D1W1MN
XNAS:KMDA chart
P/E
41.98
P/S
2.44
EPS
0.14
Div Yield, %
0.00%
Shrs. gr., 5y
5.77%
Rev. gr., 5y
4.48%
Revenues
143m
+10.19%
13,437,19415,213,59314,979,71236,274,34155,920,91472,675,00070,623,00071,925,00070,113,00077,494,000102,825,000114,469,000127,187,000133,246,000103,642,000129,339,000142,519,000
Net income
8m
P
00000260,000443,000-12,636,000-11,270,000-6,733,0006,901,00022,296,00022,251,00017,140,000-2,230,000-2,321,0008,284,000
CFO
4m
-84.91%
00010,631,371940,357-8,262,000-3,854,000-9,918,000-13,979,0001,897,0003,890,00010,546,00027,571,00019,105,000-8,819,00028,586,0004,315,000
Dividend
Jun 13, 20130.006 USD/sh
Earnings
Mar 04, 2025

Profile

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
URL
https://www.kamada.com/
IPO date
Aug 01, 2005
Employees
380
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
142,519
10.19%
129,339
24.79%
103,642
-22.22%
Cost of revenue
128,411
123,895
103,585
Unusual Expense (Income)
NOPBT
14,108
5,444
57
NOPBT Margin
9.90%
4.21%
0.05%
Operating Taxes
145
62
345
Tax Rate
1.03%
1.14%
605.26%
NOPAT
13,963
5,382
(288)
Net income
8,284
-456.92%
(2,321)
4.08%
(2,230)
-113.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,150
20
BB yield
-4.95%
0.00%
Debt
Debt current
1,384
5,460
3,785
Long-term debt
16,260
18,333
24,881
Deferred revenue
15
Other long-term liabilities
53,855
55,514
65,924
Net debt
(46,422)
(18,062)
4,509
Cash flow
Cash from operating activities
4,315
28,586
(8,819)
CAPEX
(5,850)
(3,784)
(3,730)
Cash from investing activities
(5,843)
(3,784)
(61,050)
Cash from financing activities
22,678
(9,343)
18,593
FCF
(21,004)
37,736
(21,110)
Balance
Cash
55,641
34,258
18,587
Long term investments
8,425
7,597
5,570
Excess cash
56,940
35,388
18,975
Stockholders' equity
(28,378)
(39,980)
(38,023)
Invested Capital
335,076
292,114
305,138
ROIC
4.45%
1.80%
ROCE
4.60%
2.16%
0.02%
EV
Common stock shares outstanding
53,676
44,815
44,772
Price
22.27
62.32%
13.72
-33.24%
20.55
-0.58%
Market cap
1,195,354
94.41%
614,865
-33.17%
920,060
-0.18%
EV
1,148,932
596,803
924,569
EBITDA
27,019
17,599
5,666
EV/EBITDA
42.52
33.91
163.18
Interest
1,298
914
1,277
Interest/NOPBT
9.20%
16.79%
2,240.35%